Healthcare
Viatris Inc.(VTRS)
Live Price
Offline$16.48
+1.04% today
1Y Change
+86.21%
Window
Jun 23, 2025 โ Jun 12, 2026
- Market Cap
- $17.70B
- Revenue Growth
- -3.0%
- EPS Growth
- -466.0%
- Dividend Yield
- 3.2%
Coverage: 245 bars ยท Jun 23, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Viatris Inc. (VTRS) is a Healthcare stock with a market cap of $17.70B and listed on NASDAQ. The stock last traded around $16.48 and up 86.2% across the available one-year price window (Jun 23, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of -3.0%, EPS growth of -466.0%, a dividend yield of 3.2%. What stands out right now is revenue -3.0%, EPS -466.0%, free cash flow -2.0% with operating margin -18.6% and ROIC -7.9%. The dividend matters to the case here, with a current yield around 3.2%. Valuation is more restrained than many high-expectation growth names at price/sales 1.2. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines VTRS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-3.0% vs +7.6% peer median
Operating Margin
Below sector median
-18.6% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -3.0% and EPS is at -466.0%, with operating margin around -18.6%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 3.2%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -0.5% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | -4.5% | -4.6% | -4.5% |
2026 Feb 26, 2026 | +7.1% | -2.1% | -4.7% | -12.3% |
2025 Nov 6, 2025 | +7.9% | +0.1% | +7.9% | +8.1% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VTRS
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
VTRS Max Drawdown
-19.65%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for VTRS and SPY.
Company Overview
Viatris Inc.
NASDAQ Global Select
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
- Leadership
- Scott Andrew Smith
- IPO Date
- Mar 17, 1980
- Employees
- 32.0k
- Street Address
- 1000 Mylan Boulevard
- Mailing
- Canonsburg, PA, 15317
- Region
- Canonsburg, PA, US
- Reporting Currency
- USD
- Investor Line
- 724 514 1800
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 1.2
- Price/Book
- 1.2
Growth
- Revenue
- -3.0%
- EPS
- -466.0%
- Free Cash Flow
- -2.0%
Profitability
- Gross Margin
- 35.1%
- Operating Margin
- -18.6%
- Net Margin
- -24.6%
- ROE
- -23.0%
- ROIC
- -7.9%
Balance Sheet
- Debt/Equity
- 1.00
- Current Ratio
- 1.30
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.